Novavax Appoints Dr. Robert Walker as New Head of Research and Development Efforts

Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development

On March 30, 2026, Novavax, Inc. (NASDAQ: NVAX) revealed the appointment of Dr. Robert Walker as the new Executive Vice President and Head of Research and Development (R&D). With over three decades of experience in drug and vaccine development, Dr. Walker brings a wealth of knowledge and expertise to his new role, where he will report directly to Novavax's President and CEO, John C. Jacobs.

Dr. Walker has had an extensive career in the healthcare sector, having previously held significant positions at the Biomedical Advanced Research and Development Authority in the U.S. Department of Health and Human Services. His track record in internal medicine and pulmonary and critical care medicine has equipped him with a robust foundation to lead Novavax's R&D initiatives.

Previously serving as Novavax's Chief Medical Officer, Dr. Walker has been essential in shaping the company’s R&D strategy since he joined it in 2022. His contributions have been vital in advancing vaccine and adjuvant development, thereby reinforcing scientific and clinical execution across the company’s R&D organization.

John C. Jacobs, President and Chief Executive Officer of Novavax, commended Walker's deep scientific expertise and strong leadership capabilities. He expressed confidence in Walker's ability to guide the R&D division as Novavax continues to pursue innovative solutions to major health challenges around the world. "This new appointment reflects the strength of our internal talent and our leadership team’s confidence in Bob's capacity to drive innovation and create long-term value for our technology," Jacobs stated.

Dr. Walker succeeds Dr. Ruxandra Draghia-Akli, who left Novavax to explore other opportunities. As the head of R&D, Dr. Walker will oversee both preclinical and clinical research functions, focusing on elevating the company's scientific efforts while ensuring operational excellence.

Dr. Robert Walker earned his medical degree from the University of Maryland and completed his internal medicine training at The George Washington University. His postgraduate fellowship in pulmonary and critical care medicine was completed at the University of Pennsylvania, underscoring his extensive training and preparation for his leadership role at Novavax.

Novavax's Vision for the Future

Novavax, Inc. is recognized for tackling pressing health challenges by leveraging its scientific expertise with innovative technologies. The company is well-known for its Matrix-M® adjuvant and protein-based nanoparticles, which are integral to its vaccine development. The strategic implementation of its cutting-edge technology is aimed at enhancing vaccine efficacy and accessibility, particularly in the wake of global health crises.

As the landscape of vaccine development continues to evolve, Novavax is committed to forming strategic partnerships that enhance its R&D assets and technology platform. The recent appointment of Dr. Walker is seen as a pivotal step in this journey, signaling to stakeholders the company's dedication to innovation and progress in healthcare solutions.

Conclusion

With Dr. Walker at the helm of R&D, Novavax aims to not only advance its own vaccine development projects but also foster a culture of collaboration and scientific excellence that can address the most significant health challenges facing our global community today. As the company continues to navigate the complexities of vaccine and drug development, it stands firm in its mission to innovate and collaborate in the fight against diseases worldwide.